- The FDA approves Boston Scientific's (NYSE:BSX) Spectra WaveWriter Spinal Cord Stimulation (SCS) System for the treatment of chronic pain. The company says it is the only approved SCS device that simultaneously provides paresthesia (tingling or numbness)-based and sub-perception therapy enabling patients to customize their pain management therapy.
- SCS works by sending low electrical pulse of varying frequency, pulse width and amplitude to the spinal cord to interrupt pain signals.
FDA OKs Boston Scientific's Spectra WaveWriter SCS System
Recommended For You
More Trending News
About BSX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BSX | - | - |
Boston Scientific Corporation |